Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.

Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, Burton DR.

PLoS Pathog. 2009 May;5(5):e1000433. doi: 10.1371/journal.ppat.1000433. Epub 2009 May 15.

2.

Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma.

Davis KL, Bibollet-Ruche F, Li H, Decker JM, Kutsch O, Morris L, Salomon A, Pinter A, Hoxie JA, Hahn BH, Kwong PD, Shaw GM.

J Virol. 2009 Feb;83(3):1240-59. doi: 10.1128/JVI.01743-08. Epub 2008 Nov 19.

3.

Vaccines: correlates of vaccine-induced immunity.

Plotkin SA.

Clin Infect Dis. 2008 Aug 1;47(3):401-9. doi: 10.1086/589862. Review.

PMID:
18558875
4.

Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope.

Zolla-Pazner S, Cohen SS, Krachmarov C, Wang S, Pinter A, Lu S.

Virology. 2008 Mar 15;372(2):233-46. Epub 2007 Dec 3.

5.

Development of an HIV-1 reference panel of subtype B envelope clones isolated from the plasma of recently infected individuals.

Schweighardt B, Liu Y, Huang W, Chappey C, Lie YS, Petropoulos CJ, Wrin T.

J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):1-11. Erratum in: J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):528.

PMID:
17514017
6.

Seroprevalence of vaccine preventable and blood transmissible viral infections (measles, mumps, rubella, polio, HBV, HCV and HIV) in medical students.

Wicker S, Rabenau HF, Gottschalk R, Doerr HW, Allwinn R.

Med Microbiol Immunol. 2007 Sep;196(3):145-50. Epub 2007 Feb 2.

PMID:
17273881
9.

Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.

Mascola JR, Sambor A, Beaudry K, Santra S, Welcher B, Louder MK, Vancott TC, Huang Y, Chakrabarti BK, Kong WP, Yang ZY, Xu L, Montefiori DC, Nabel GJ, Letvin NL.

J Virol. 2005 Jan;79(2):771-9.

10.

The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1.

Zolla-Pazner S, Zhong P, Revesz K, Volsky B, Williams C, Nyambi P, Gorny MK.

AIDS Res Hum Retroviruses. 2004 Nov;20(11):1254-8.

PMID:
15588347
11.

Immunogenicity and protective efficacy of influenza vaccination.

Hannoun C, Megas F, Piercy J.

Virus Res. 2004 Jul;103(1-2):133-8. Review. No abstract available.

PMID:
15163501
12.

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.

Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng-Mayer C, Moore JP, Burton DR.

J Virol. 2001 Sep;75(17):8340-7.

13.

The antiviral activity of antibodies in vitro and in vivo.

Parren PW, Burton DR.

Adv Immunol. 2001;77:195-262. Review. No abstract available.

PMID:
11293117
14.

Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes.

Nyambi PN, NĂ¡das A, Mbah HA, Burda S, Williams C, Gorny MK, Zolla-Pazner S.

J Virol. 2000 Nov;74(22):10670-80.

15.

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.

Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, Lewis MG.

Nat Med. 2000 Feb;6(2):207-10.

PMID:
10655111
16.

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.

Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, Cavacini LA, Posner MR, Katinger H, Stiegler G, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Lu Y, Wright JE, Chou TC, Ruprecht RM.

Nat Med. 2000 Feb;6(2):200-6.

PMID:
10655110
17.

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, Ross W, Willey R, Cho MW, Martin MA.

Nat Med. 1999 Feb;5(2):204-10.

PMID:
9930869
18.

On the specificity of antibodies.

Richards FF, Konigsberg WH, Rosenstein RW, Varga JM.

Science. 1975 Jan 17;187(4172):130-7. Review. No abstract available.

PMID:
46122

Supplemental Content

Support Center